[1]
|
Di Candia, L., Gomez, E., Venereau, E., et al. (2017) HMGB1 Is Upregulated in the Airways in Asthma and Potentiates Airway Smooth Muscle Contraction via TLR4. Journal of Allergy and Clinical Immunology, 140, 584-587.
https://doi.org/10.1016/j.jaci.2016.11.049
|
[2]
|
Papi, A., Brightling, C., Pedersen, S.E., et al. (2018) Asthma. The Lancet, 391, 783-800.
https://doi.org/10.1016/S0140-6736(17)33311-1
|
[3]
|
Thomas, R., Paolo, S., Pierre-Olivier, B., et al. (2018) Diagnosis and Management of Asthma—The Swiss Guidelines. Respiration; International Review of Thoracic Diseases, 95, 364-380. https://doi.org/10.1159/000486797
|
[4]
|
Gong, F., Pan, Y.H., Huang, X., et al. (2017) From Bench to Bedside: Therapeutic Potential of Interleukin-9 in the Treatment of Asthma. Experimental and Therapeutic Medicine, 13, 389-394. https://doi.org/10.3892/etm.2017.4024
|
[5]
|
Marsh, A.M., Nguyen, A.H., Parker, T.M., et al. (2017) Clinical Use of High Mobility Group Box 1 and the Receptor for Advanced Glycation end Products in the Prognosis and Risk Stratification of Heart Failure: A Literature Review. Canadian Journal of Physiology and Pharmacology, 95, 253-259. https://doi.org/10.1139/cjpp-2016-0299
|
[6]
|
Liu, Y., Zhang, H., Ni, R., et al. (2017) IL-4R Suppresses Airway Inflammation in Bronchial Asthma by Inhibiting the IL-4/STAT6 Pathway. Pulmonary Pharmacology and Therapeutics, 43, 32-38.
https://doi.org/10.1016/j.pupt.2017.01.006
|
[7]
|
Chen, S., Wang, Y., Gong, G., et al. (2015) Ethyl Pyruvate Attenuates Murine Allergic Rhinitis Partly by Decreasing High Mobility Group Box 1 Release. Experimental Biology and Medicine, 240, 1490-1499.
https://doi.org/10.1177/1535370214566563
|
[8]
|
Hou, C., Kong, J., Liang, Y., et al. (2015) HMGB1 Contributes to Allergen-Induced Airway Remodeling in a Murine Model of Chronic Asthma by Modulating Airway Inflammation and Activating Lung Fibroblasts. Cellular & Molecular Immunology, 12, 409-423. https://doi.org/10.1038/cmi.2014.60
|
[9]
|
Shim, E.-J., Chun, E., Lee, H.-S., et al. (2012) The Role of High-Mobility Group Box-1 (HMGB1) in the Pathogenesis of Asthma. Clinical & Experimental Allergy, 42, 958-965. https://doi.org/10.1111/j.1365-2222.2012.03998.x
|
[10]
|
陈亚红. 2021年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志(电子版), 2021, 13(1): 16-37.
|
[11]
|
Kim, V., Rogers, T.J. and Criner, G.J. (2008) New Concepts in the Pathobiology of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 5, 478-485. https://doi.org/10.1513/pats.200802-014ET
|
[12]
|
Yang, H., et al. (2012) Novel Insights for High Mobility Group Box 1 Protein-Mediated Cellular Immune Response in Sepsis: A Systemic Review. World Journal of Emergency Medicine, 3, 165-171.
https://doi.org/10.5847/wjem.j.issn.1920-8642.2012.03.001
|
[13]
|
Huan, Y., Haichao, W. and Ulf, A. (2020) Targeting Inflammation Driven by Hmgb1. Frontiers in Immunology, 11, 484. https://doi.org/10.3389/fimmu.2020.00484
|
[14]
|
Shang, G.-H., Jia, C.-Q., Tian, H., et al. (2009) Serum High Mobility Group Box Protein 1 as a Clinical Marker for Non-Small Cell Lung Cancer. Respiratory Medicine, 103, 1949-1953. https://doi.org/10.1016/j.rmed.2009.05.019
|
[15]
|
Lee, H., Park, J., Kim, W.J., et al. (2017) Blockade of Rage Ameliorates Elastase-Induced Emphysema Development and Progression via Rage-Damp Signaling. The FASEB Journal, 31, 2076-2098.
https://doi.org/10.1096/fj.201601155R
|
[16]
|
Liu, W., Liu, Z.G., Zhang, W.D. and Cai, S.X. (2018) Ulinastatin Protects the Lungs of Copd Rats through the Hmgb1/tlr4 Signaling Pathway. Oncology Letters, 16, 4057-4063.
|
[17]
|
Wang, C.M., Jiang, M. and Wang, H.J. (2013) Effect of NF-κB Inhibitor on High-Mobility Group Protein B1 Expression in a COPD Rat Model. Molecular Medicine Reports, 7, 499-502. https://doi.org/10.3892/mmr.2012.1181
|
[18]
|
Schwartz, D.A. (2016) Idopathich Pulmonary Fibrosis Is a Complex Genetic Disorder. Transactions of the American Clinical and Climatological Association, 127, 34-45.
|
[19]
|
King, T.E., Pardo, A. and Selman, M. (2011) Idiopathic Pulmonary Fibrosis. The Lancet, 378, 1949-1961.
https://doi.org/10.1016/S0140-6736(11)60052-4
|
[20]
|
Li, L.-C., Gao, J. and Li, J. (2014) Emerging Role of HMGB1 in Fibrotic Diseases. Journal of Cellular and Molecular Medicine, 18, 2331-2339. https://doi.org/10.1111/jcmm.12419
|
[21]
|
Hubbard, R.B., Smith, C., Le Jeune, I., et al. (2008) The Association between Idiopathic Pulmonary Fibrosis and Vascular Disease. American Journal of Respiratory and Critical Care Medicine, 178, 1257-1261.
https://doi.org/10.1164/rccm.200805-725OC
|
[22]
|
Sprunger, D.B., Olson, A.L., Huie, T.J., et al. (2012) Pulmonary Fibrosis Is Associated with an Elevated Risk of Thromboembolic Disease. European Respiratory Journal, 39, 125-132. https://doi.org/10.1183/09031936.00041411
|
[23]
|
Shigemitsu, H. and Azuma, A. (2011) Sarcoidosis and Interstitial Pulmonary Fibrosis; Two Distinct Disorders or Two Ends of the Same Spectrum. Current Opinion in Pulmonary Medicine, 17, 303-307.
https://doi.org/10.1097/MCP.0b013e3283486d52
|
[24]
|
Kim, D.E., Min, K., Kim, J.S., et al. (2012) High-Mobility Group Box-1 Protein Induces Mucin 8 Expression through the Activation of the JNK and PI3K/Akt Signal Pathways in Human Airway Epithelial Cells. Biochemical and Biophysical Research Communications, 421, 436-441. https://doi.org/10.1016/j.bbrc.2012.03.131
|
[25]
|
Wang, Q., Wang, J., Wang, J., et al. (2017) HMGB1 Induces Lung Fibroblast to Myofibroblast Differentiation through NF-κB-Mediated TGF-β1 Release. Molecular Medicine Reports, 15, 3062-3068.
https://doi.org/10.3892/mmr.2017.6364
|
[26]
|
He, M., Kubo, H., Ishizawa, K., et al. (2007) The Role of the Receptor for Advanced Glycation EN-Products in Lung Fibrosis. The American Journal of Physiology-Lung Cellular and Molecular Physiology, 293, L1427-L1436.
https://doi.org/10.1152/ajplung.00075.2007
|
[27]
|
Pedroza, M., Le, T.T., Lewis, K., et al. (2016) STAT-3 Contributes to Pulmonary Fibrosis through Epithelial Injury and Fibroblast-Myofibroblast Differentiation. FASEB Journal, 30, 129-140. https://doi.org/10.1096/fj.15-273953
|
[28]
|
Tang, L.-Y., Heller, M., Meng, Z., et al. (2017) Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. Journal of Biological Chemistry, 292, 4302-4312. https://doi.org/10.1074/jbc.M116.773085
|
[29]
|
Li, C., Yu, Y., Li, W., et al. (2017) Phycocyanin Attenuates Pulmonary Fibrosis via the TLR2-MyD88-NF-κB Signaling Pathway. Scientific Reports, 7, Article No. 5843. https://doi.org/10.1038/s41598-017-06021-5
|
[30]
|
Hamada, N., Maeyama, T., Kawaguchi, T., et al. (2008) The Role of High Mobility Group Box1 in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 39, 440-447.
https://doi.org/10.1165/rcmb.2007-0330OC
|
[31]
|
Grief, S.N. and Loza, J.K. (2018) Guidelines for the Evaluation and Treatment of Pneumonia. Primary Care: Clinics in Office Practice, 45, 485-503. https://doi.org/10.1016/j.pop.2018.04.001
|
[32]
|
López Del Prado, G.R., Hernán García, C., Moreno Cea, L., et al. (2014) Malaria in Developing Countries. The Journal of Infection in Developing Countries, 8, 1-4. https://doi.org/10.3855/jidc.4610
|
[33]
|
Barbier, F. andremont, A., Wolff, M., et al. (2013) Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: Recent Advances in Epidemiology and Management. Current Opinion in Pulmonary Medicine, 19, 216-228.
https://doi.org/10.1097/MCP.0b013e32835f27be
|
[34]
|
Ottosen, J. and Evans, H. (2014) Pneumonia: Challenges in the Definition, Diagnosis, and Management of Disease. Surgical Clinics of North America, 94, 1305-1317. https://doi.org/10.1016/j.suc.2014.09.001
|
[35]
|
Ding, Y., Chu, C., Li, Y.Q., et al. (2018) High Expression of HMGB1 in Children with Refractory Mycoplasma pneumoniae Pneumonia. BioMed Central, 18, 439. https://doi.org/10.1186/s12879-018-3346-8
|
[36]
|
Tang, Z., Zang, N., Fu, Y., et al. (2018) HMGB1 Mediates HAdV-7 Infection-Induced Pulmonary Inflammation in Mice. Biochemical and Biophysical Research Communications, 501, 1-8. https://doi.org/10.1016/j.bbrc.2018.03.145
|
[37]
|
Morbini, P., Villa, C., Campo, I., et al. (2006) The Receptor for Advanced Glycation end Products and Its Ligands: A New Inflammatory Pathway in Lung Disease? Modern Pathology, 19, 1437-1445.
https://doi.org/10.1038/modpathol.3800661
|
[38]
|
Alpkvist, H., Athlin, S., Mölling, P., et al. (2018) High HMGB1 Levels in Sputum Are Related to Pneumococcal Bacteraemia But Not to Disease Severity in Community-Acquired Pneumonia. Scientific Reports, 8, Article No. 13428.
https://doi.org/10.1038/s41598-018-31504-4
|
[39]
|
Wang, H.-L., Tsao, S.-M., Yeh, C.-B., et al. (2017) Circulating Level of High Mobility Group Box-1 Predicts the Severity of Community-Acquired Pneumonia: Regulation of Inflammatory Responses via the c-Jun N-Terminal Signaling Pathway in Macrophages. Molecular Medicine Reports, 16, 2361-2366. https://doi.org/10.3892/mmr.2017.6892
|
[40]
|
Hou, X.Q., Qin, J.L., Zheng, X.X., et al. (2014) Potential Role of High-Mobility Group Box 1 Protein in the Pathogenesis of Influenza H5N1 Virus Infection. Acta Virologica, 58, 69-75. https://doi.org/10.4149/av_2014_01_69
|
[41]
|
Ettinger, D.S., Wood, D.E., Akerley, W., et al. (2016) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4. Journal of the National Comprehensive Cancer Network, 14, 255-264. https://doi.org/10.6004/jnccn.2016.0031
|
[42]
|
Herbst, R.S., Morgensztern, D., et al. (2018) The Biology and Management of Non-Small Cell Lung Cancer. Nature: International Weekly Journal of Science, 553, 446-454. https://doi.org/10.1038/nature25183
|
[43]
|
Wu, L. and Yang, L. (2018) The Function and Mechanism of HMGB1 in Lung Cancer and Its Potential Therapeutic Implications. Oncology Letters, 15, 6799-6805. https://doi.org/10.3892/ol.2018.8215
|
[44]
|
Taguchi, A., Blood, D.C., del Toro, G., et al. (2000) Blockade of RAGE-Amphoterin Signalling Suppresses Tumour Growth and Metastases. Nature, 405, 354-360. https://doi.org/10.1038/35012626
|
[45]
|
Niki, M., Yokoi, T., Kurata, T., et al. (2017) New Prognostic Biomarkers and Therapeutic Effect of Bevacizumab for Patients with Non-Small-Cell Lung Cancer. Lung Cancer: Targets and Therapy, 8, 91-99.
https://doi.org/10.2147/LCTT.S138887
|
[46]
|
Shang, G.-H., Jia, C.-Q., Tian, H., et al. (2009) Serum High Mobility Group Box Protein 1 as a Clinical Marker for Non-Small Cell Lung Cancer. Respiratory Medicine, 103, 1949-1953. https://doi.org/10.1016/j.rmed.2009.05.019
|
[47]
|
Carmeliet, P. (2005) Angiogenesis in Life, Disease and Medicine. Nature: International Weekly Journal of Science, 438, 932-936. https://doi.org/10.1038/nature04478
|
[48]
|
Pan, B., Chen, D., Huang, J., et al. (2014) HMGB1-Mediated Autophagy Promotes Docetaxel Resistance in Human Lung Adenocarcinoma. Molecular Cancer, 13, 165. https://doi.org/10.1186/1476-4598-13-165
|